The Reven Team is aware of the recent SEC action against the company and some of its executives. Reven denies the allegations and is working through counsel to respond to them.
Launching a new generation of pharmacological solutions that target the root cause of diseases by restoring immune system homeostasis.
RJX by Reven
RJX is a stand-alone drug and a flexible formulation developed with a proprietary process to target areas of immunologic function without the need for stabilizers and preservatives.
“Our goal is to impact multiple disease indications stemming from inflammation ranging from cancer to cardiovascular disease in the same way antibiotics impacted infectious disease when they were discovered nearly a century ago.”
Michael Volk / Co-Founder & CSO
Reven Holdings, Inc. 2921 W. 120th Ave / Suite 220 Westminster, CO 80234
1-866-REVEN-RX (1-866-738-3679) email@example.com
© 2021 Reven Holdings, Inc. — All rights reserved.